Milestone Pharmaceuticals (NASDAQ:MIST) Releases Earnings Results, Misses Expectations By $0.56 EPS

Milestone Pharmaceuticals (NASDAQ:MIST) issued its quarterly earnings results on Tuesday. The company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.56), Fidelity Earnings reports.

NASDAQ:MIST traded up $1.24 during trading hours on Wednesday, reaching $18.04. The stock had a trading volume of 110 shares, compared to its average volume of 35,768. The stock has a 50 day moving average of $19.55. Milestone Pharmaceuticals has a 12-month low of $15.09 and a 12-month high of $27.95.

A number of analysts recently commented on MIST shares. Cowen started coverage on Milestone Pharmaceuticals in a research report on Monday, June 3rd. They set an “outperform” rating and a $32.00 price target for the company. CIBC started coverage on Milestone Pharmaceuticals in a research report on Tuesday, June 4th. They set an “outperform” rating and a $32.00 price target for the company. Jefferies Financial Group started coverage on Milestone Pharmaceuticals in a research report on Monday, June 3rd. They set a “buy” rating and a $28.00 price target for the company. Piper Jaffray Companies started coverage on Milestone Pharmaceuticals in a research report on Monday, June 3rd. They set an “overweight” rating and a $26.50 price target for the company. Finally, Oppenheimer started coverage on Milestone Pharmaceuticals in a research report on Tuesday, June 4th. They set an “outperform” rating and a $32.00 price target for the company. Five research analysts have rated the stock with a buy rating, Milestone Pharmaceuticals currently has an average rating of “Buy” and an average target price of $30.10.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

Read More: How to Trade Using Analysts Ratings

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply